The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome, a Cholestatic Liver Disease
Latest Information Update: 25 May 2023
At a glance
- Drugs Maralixibat (Primary)
- Indications Alagille syndrome; Cholestasis
- Focus Therapeutic Use
- Acronyms ITCH
- Sponsors Lumena Pharmaceuticals; Mirum Pharmaceuticals; Shire Pharmaceuticals
- 19 May 2023 According to a Mirum Pharmaceuticals media release, integrated analysis of two studies presented at the 55th European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting.
- 24 Jun 2022 According to a Mirum Pharmaceuticals media release, data from this study presented at the 54th Annual European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting (ESPGHAN)
- 13 Jun 2022 According to a Mirum Pharmaceuticals media release, data from this study will be presented at the 54th Annual European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting (ESPGHAN).